Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy
Abstract
AIM: The prognostic role of eosinophils in cancer has been controversial. Some entities such as gastrointestinal cancers show a better survival, while others such as Hodgkin's lymphoma a worse survival in patients with eosinophilia. Patients who exhibited an increase in eosinophils upon therapy with ipilimumab or pembrolizumab were shown to survive longer. We wanted to investigate whether eosinophilia is a prognostic marker in metastatic melanoma. METHODS: In total, 173 patients with metastatic melanoma from our data base (median age 60 years; n = 86 with immunotherapy, n = 87 without immunotherapy) were analyzed for eosinophil counts and survival over the course of 12 years. Eosinophilic count was detected by peripheral blood smear. The ethical committee had approved this retrospective study. RESULTS: Melanoma patients with eosinophilia at any point in their course of disease show a trend toward longer survival independently of their therapy. There is a statistically significant difference for the patients who survive at least 12 months (p < 0.005). In patients with checkpoint inhibitor therapy, survival was significantly prolonged in every patient with eosinophilia (p < 0.05). Furthermore, 69% of the patients treated with immunotherapy experienced at least once an eosinophilia of 5% or greater compared with 46% in the immunotherapy naive-group; for an eosinophilia of 10% values were 30 and 9%, respectively. Interestingly, in patients with more than 20% eosinophils (n = 7) survival was prolonged with a median of 35 months (range 19-60 months) as compared with 16 months (range 1-117 months). CONCLUSION: Eosinophilia is a prognostic marker in patients with metastatic melanoma.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ICI-related eosinophilia was described initially with ipilimumab and later with PD-1/PD-L1 inhibitors; it was frequently associated with a favorable response to ICIs.
“ICI-related eosinophilia was described initially with ipilimumab 120 and later with PD-1/PD-L1 inhibitors; additionally, it was frequently associated with a favorable response to ICIs.121e123”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [120]
Cites
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,373 · see citing works
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · see citing works
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · see citing works
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012 · see citing works
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589 · see citing works
Self-citationCarretero, R., Sektioglu, I. M., Garbi, N., Salgado, O. C., Beckhove, P., & Hämmerling, G. J. (2015) · Nature Immunology · doi:10.1038/ni.3159 · Cited by 501 · see citing works
Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367 · see citing works
Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A. M. M., Routier, E., & Robert, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt027 · Cited by 318 · see citing works
Ikutani, M., Yanagibashi, T., Ogasawara, M., Tsuneyama, K., Yamamoto, S., Hattori, Y., Kouro, T., Itakura, A., Nagai, Y., Τακακι, S., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101270 · Cited by 314 · see citing works
Mackensen, A., Meidenbauer, N., Vogl, S., Laumer, M., Berger, J., & Andreesen, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1100 · Cited by 297 · see citing works
Davis, B. P., & Rothenberg, M. E. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0196 · Cited by 262 · see citing works
Tumour-associated eosinophilia: a review.
Lowe, D. G., Jorizzo, J. R., & Hutt, M. (1981) · Journal of Clinical Pathology · doi:10.1136/jcp.34.12.1343 · Cited by 258 · see citing works
Simson, L., Ellyard, J. I., Dent, L. A., MATTHAEI, K. I., Rothenberg, M. E., Foster, P. S., Smyth, M. J., & Parish, C. R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4222 · Cited by 217 · see citing works
Legrand, F., Driss, V., Delbeke, M., Loiseau, S., Hermann, E., Dombrowicz, D., & Capron, M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000446 · Cited by 177 · see citing works
Cormier, S. A., Taranova, A. G., Bedient, C. E., Nguyen, T. D., Protheroe, C. A., Pero, R. S., Dimina, D., Ochkur, S. I., O'Neill, K. R., Colbert, D. C., et al. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0106027 · Cited by 176 · see citing works
Eosinophilic Granulocytes and Damage-associated Molecular Pattern Molecules (DAMPs)
Lotfi, R., Lee, J. J., & Lotze, M. T. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211324.53396.f6 · Cited by 167 · see citing works
Eosinophils in Cancer: Favourable or Unfavourable?
Sakkal, S., Miller, S., Apostolopoulos, V., & Nurgali, K. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160119094313 · Cited by 161 · see citing works
Samoszuk, M. K. (1997) · PubMed · Cited by 156 · see citing works
Involvement of eosinophils in the anti-tumor response
Gatault, S., Legrand, F., Delbeke, M., Loiseau, S., & Capron, M. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1288-3 · Cited by 132 · see citing works
Prizment, A. E., Vierkant, R. A., Smyrk, T. C., Tillmans, L. S., Lee, J. J., Sriramarao, P., Nelson, H. H., Lynch, C. F., Thibodeau, S. N., Church, T. R., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.42 · Cited by 97 · see citing works
Lipson, E. J., Sharfman, W. H., Chen, S., McMiller, T. L., Pritchard, T. S., Salas, J. T., Sartorius-Mergenthaler, S., Freed, I., Ravi, S., Wang, H., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0572-3 · Cited by 94 · see citing works
Faries, M. B., Hsueh, E. C., Ye, X., Hoban, M., & Morton, D. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1540 · Cited by 91 · see citing works
Rivoltini, L., Colombo, M. P., Parmiani, G., Viggiano, V., Spinazzé, S., Santoro, A., & Takatsu, K. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540103 · Cited by 69 · see citing works
Schaefer, J. T., Patterson, J. W., Deacon, D. H., Smolkin, M. E., Petroni, G. R., Jackson, E. M., & Slingluff, C. L. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-79 · Cited by 48 · see citing works
Ohashi, Y., Ishibashi, S., Suzuki, T., Shineha, R., Moriya, T., Satomi, S., & Sasano, H. (2000) · PubMed · Cited by 44 · see citing works
Murine hypodense eosinophils induce tumour cell apoptosis by a granzyme B-dependent mechanism
Costain, D. J., Guha, A. K., Liwski, R., & Lee, T. D. G. (2001) · Cancer Immunology Immunotherapy · doi:10.1007/pl00006690 · Cited by 35 · see citing works
The appearance of hypodense eosinophils during interleukin-2 treatment
Sedgwick, J. B., Frick, W. E., Sondel, P. M., Hank, J. A., Borden, E. C., & Busse, W. W. (1990) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(90)90093-j · Cited by 32 · see citing works
Rodgers, S., Rees, R. C., & Hancock, B. W. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb04824.x · Cited by 28 · see citing works
Predictive immune markers in advanced melanoma patients treated with ipilimumab
Umansky, V., Utikal, J. S., & Gebhardt, C. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1158901 · Cited by 25 · see citing works
Eosinophils enable the antitumour T cell response
Minton, K. (2015) · Nature reviews. Immunology · doi:10.1038/nri3861 · Cited by 16 · see citing works
Samoszuk, M. K., Deng, T., Hamamura, M. J., Su, M., Asbrock, N., & Nalcioğlu, O. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63310-x · Cited by 16 · see citing works
Capobianco, A., Manfredi, A. A., Monno, A., Rovere, P. Q., & Rugarli, C. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318174a512 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
A new dawn for eosinophils in the tumour microenvironment
Grisaru‐Tal, S., Itan, M., Klion, A. D., & Munitz, A. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0283-9 · Cited by 306 · see citing works
Eosinophils: The unsung heroes in cancer?
Varricchi, G., Galdiero, M. R., Loffredo, S., Lucarini, V., Marone, G., Mattei, F., Marone, G., & Schiavoni, G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1393134 · Cited by 280 · see citing works
Diehl, A., Yarchoan, M. M., Hopkins, A., Jaffee, E. M., & Grossman, S. A. (2017) · Oncotarget · doi:10.18632/oncotarget.23217 · Cited by 247 · see citing works
Exploiting innate immunity for cancer immunotherapy
Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 236 · see citing works
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222 · see citing works
Ju, M., Bi, J., Wei, Q., Jiang, L., Guan, Q., Zhang, M., Song, X., Chen, T., Fan, J., Li, X., et al. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa345 · Cited by 183 · see citing works
Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma
Jacquelot, N., Seillet, C., Wang, M., Pizzolla, A., Liao, Y., Hediyeh-zadeh, S., Grisaru‐Tal, S., Louis, C., Huang, Q., Schreuder, J., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00943-z · Cited by 183 · see citing works
Gigon, L., Fettrelet, T., Yousefi, S., Simon, D., & Simon, H. (2023) · Allergy · doi:10.1111/all.15751 · Cited by 142 · see citing works
Eosinophil–lymphocyte interactions in the tumor microenvironment and cancer immunotherapy
Grisaru‐Tal, S., Rothenberg, M. E., & Munitz, A. (2022) · Nature Immunology · doi:10.1038/s41590-022-01291-2 · Cited by 131 · see citing works
Opposing roles of eosinophils in cancer
Simon, S. C. S., Utikal, J., & Umansky, V. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2255-4 · Cited by 128 · see citing works
Rosner, S., Kwong, E., Shoushtari, A. N., Friedman, C. F., Warner, A. B., Brady, M. S., Coit, D. G., Callahan, M. K., Wolchok, J. D., Chapman, P. B., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1356 · Cited by 124 · see citing works
Nakamura, Y., Tanaka, R., Maruyama, H., Ishitsuka, Y., Okiyama, N., Watanabe, R., Fujimoto, M., & Fujisawa, Y. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy201 · Cited by 114 · see citing works
Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
Simon, S. C. S., Hu, X., Panten, J., Grees, M., Renders, S., Thomas, D., Weber, R., Schulze, T. J., Utikal, J. S., & Umansky, V. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1727116 · Cited by 88 · see citing works
Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies.
Bernard-Tessier, A., Jeanville, P., Champiat, S., Lazarovici, J., Voisin, A.-L., Mateus, C., Lambotte, O., Annereau, M., & Michot, J.-M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.017 · Cited by 78 · see citing works
AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer
Jensen‐Jarolim, E., Bax, H. J., Bianchini, R., Crescioli, S., Daniels‐Wells, T. R., Dombrowicz, D., Fiebiger, E., Gould, H. J., Irshad, S., Janda, J., et al. (2017) · Allergy · doi:10.1111/all.13311 · Cited by 76 · see citing works
Cheng, J., Luo, W., Sun, C., Jin, Z., Zeng, X., Alexander, P. B., Gong, Z., Xia, X., Ding, X., Xu, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc7609 · Cited by 71 · see citing works
Nicotinamide inhibits melanoma in vitro and in vivo
Scatozza, F., Moschella, F., D’Arcangelo, D., Rossi, S., Tabolacci, C., Giampietri, C., Proietti, E., Facchiano, F., & Facchiano, A. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01719-3 · Cited by 68 · see citing works
Biomarkers to predict prognosis and response to checkpoint inhibitors
Yuasa, T., Masuda, H., Yamamoto, S., Numao, N., & Yonese, J. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1122-1 · Cited by 66 · see citing works
Frigerio, S., Lartey, D. A., D’Haens, G., & Grootjans, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312739 · Cited by 64 · see citing works
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
Pagni, F., Guerini‐Rocco, E., Schultheis, A. M., Grazia, G., Rijavec, E., Ghidini, M., Lopez, G., Venetis, K., Croci, G. A., Malapelle, U., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215452 · Cited by 61 · see citing works
Kunert, A., Basak, E. A., Hurkmans, D. P., Balcioglu, H. E., Klaver, Y., van Brakel, M., Oostvogels, A. A. M., Lamers, C. H. J., Bins, S., Koolen, S. L. W., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0608-y · Cited by 59 · see citing works
Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
Filipović, A., Miller, G., & Bolen, J. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00155 · Cited by 60 · see citing works
Scanvion, Q., Béné, J., Gautier, S., Grandvuillemin, A., Le Beller, C., Chenaf, C., Etienne, N., Brousseau, S., Cortot, A. B., Mortier, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1722022 · Cited by 59 · see citing works
Cancer Immunoediting by Innate Lymphoid Cells
Wagner, M., & Koyasu, S. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.03.004 · Cited by 54 · see citing works
Eosinophils in the Tumor Microenvironment
Mattei, F., Andreone, S., Marone, G., Gambardella, A. R., Loffredo, S., Varricchi, G., & Schiavoni, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_1 · Cited by 53 · see citing works
Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles
Arkhypov, I., Lasser, S., Petrova, V., Weber, R., Groth, C., Utikal, J. S., Altevogt, P., & Umansky, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176319 · Cited by 50 · see citing works
Zhang, H., Zhao, W., Li, X., & He, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s315998 · Cited by 49 · see citing works
Eosinophils and Lung Cancer: From Bench to Bedside
Sibille, A., Corhay, J.-L., Louis, R. E., Ninane, V., Jérusalem, G., & Duysinx, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095066 · Cited by 48 · see citing works
Prognostic biomarkers of cutaneous melanoma
Ding, L., Gosh, A., Lee, D. J., Emri, G., Huss, W. J., Bogner, P. N., & Paragh, G. (2022) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/phpp.12770 · Cited by 46 · see citing works
Holub, K., & Biete, A. (2018) · BMC Cancer · doi:10.1186/s12885-018-5131-x · Cited by 45 · see citing works
Krishnan, T., Tomita, Y., & Roberts‐Thomson, R. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0070 · Cited by 40 · see citing works
Alves, A., Dias, M., Campainha, S., & Barroso, A. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3525 · Cited by 41 · see citing works
Ouwerkerk, W., van den Berg, M., van der Niet, S., Limpens, J., & Luiten, R. M. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000589 · Cited by 37 · see citing works
Schwarze, J. K., Tijtgat, J., Awada, G., Cras, L., Vasaturo, A., Bagnall, C. J., Forsyth, R. G., Dufait, I., Tuyaerts, S., Riet, I. V., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005141 · Cited by 37 · see citing works
Ghebeh, H., Elshenawy, M. A., Alsayed, A., & Al‐Tweigeri, T. (2022) · Immunotherapy · doi:10.2217/imt-2021-0149 · Cited by 37 · see citing works
Ma, Y., Ma, X., Wang, J., Wu, S., Wang, J., & Cao, B. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02695-y · Cited by 34 · see citing works
Harnessing myeloid cells in cancer
Park, S., Pylaeva, E., Bhuria, V., Gambardella, A. R., Schiavoni, G., Mougiakakos, D., Kim, S.-H., & Jabłońska, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02249-2 · Cited by 35 · see citing works
Reinventing type 2 immunity in cancer
Wagner, M., Nishikawa, H., & Koyasu, S. (2025) · Nature · doi:10.1038/s41586-024-08194-2 · Cited by 33 · see citing works
Onesti, C. E., Josse, C., Boulet, D., Thiry, J., Beaumecker, B., Bours, V., & Jérusalem, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1761176 · Cited by 31 · see citing works
Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma
Krückel, A., Moreira, A., Fröhlich, W., Schuler, G., & Heinzerling, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5384-z · Cited by 30 · see citing works
Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma
Puglisi, R., Bellenghi, M., Pontecorvi, G., Pallante, G., Carè, A., & Mattia, G. (2021) · Cancers · doi:10.3390/cancers13122875 · Cited by 32 · see citing works
Eosinophilia in cancer and its regulation by sex hormones
Artham, S., Chang, C., & McDonnell, D. P. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.11.002 · Cited by 29 · see citing works
Takeuchi, E., Kondo, K., Okano, Y., Ichihara, S., Kunishige, M., Kadota, N., Machida, H., Hatakeyama, N., Naruse, K., Ogino, H., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15100 · Cited by 27 · see citing works
Onesti, C. E., Josse, C., Poncin, A., Frères, P., Poulet, C., Bours, V., & Jérusalem, G. (2018) · Oncotarget · doi:10.18632/oncotarget.26120 · Cited by 26 · see citing works
Goerig, N. L., Frey, B., Korn, K., Fleckenstein, B., Überla, K., Schmidt, M. A., Dörfler, A., Engelhorn, T., Eyüpoglu, I. Y., Rühle, P. F., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3195 · Cited by 25 · see citing works
Caliman, E., Fancelli, S., Ottanelli, C., Mazzoni, F., Paglialunga, L., Lavacchi, D., Michelet, M. R. G., Giommoni, E., Napolitano, B., Scolari, F., et al. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100603 · Cited by 24 · see citing works
Herrmann, T., Ginzac, A., Molnar, I., Bailly, S., Durando, X., & Mahammedi, H. (2021) · Cancer Medicine · doi:10.1002/cam4.4208 · Cited by 24 · see citing works
Lou, Y., Marin-Acevedo, J. A., Vishnu, P., Manochakian, R., Dholaria, B., Soyano, A. E., Luo, Y., Zhang, Y., & Knutson, K. L. (2019) · Immunotherapy · doi:10.2217/imt-2018-0128 · Cited by 23 · see citing works
Gambichler, T., Brown, V., Steuke, A. ‐., Schmitz, L., Stockfleth, E., & Susok, L. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14629 · Cited by 22 · see citing works
Huang, Y., Wu, L., Sun, Y., Li, J., Mao, N., Yang, Y. A., Zhao, M., & Ren, S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18215 · Cited by 22 · see citing works
Eosinophils and melanoma: Implications for immunotherapy
Robinson, I., Lucia, G. S., Li, A. R., Oberholtzer, N. P., Plante, J. G., Quinn, K. M., Reuben, D. Y., Mehrotra, S., & Valdebran, M. (2021) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13025 · Cited by 22 · see citing works
Tomsitz, D., Schlaak, M. S., Zierold, S., Pesch, G., Schulz, T. U., Müller, G., Zecha, C., French, L. E., & Heinzerling, L. (2022) · Cancers · doi:10.3390/cancers14133282 · Cited by 23 · see citing works
Ohkuma, R., Kubota, Y., Horiike, A., Ishiguro, T., Hirasawa, Y., Ariizumi, H., Watanabe, M., Onoue, R., Ando, K., Tsurutani, J., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001731 · Cited by 20 · see citing works
Ammann, N. L., Schwietzer, Y. F., Meß, C., Stadler, J.-C., Geidel, G., Kött, J., Pantel, K., Schneider, S. W., Utikal, J. S., Bauer, A. T., et al. (2022) · Cancers · doi:10.3390/cancers14225676 · Cited by 23 · see citing works
Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
Loo, K. L., Smithy, J. W., Postow, M. A., & Warner, A. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.810388 · Cited by 20 · see citing works
Toussaint, F., Hammon, M., Erdmann, M., Moreira, A., Kirchberger, M. C., Schuler, G., Schett, G., & Heinzerling, L. (2019) · Rheumatology · doi:10.1093/rheumatology/kez164 · Cited by 19 · see citing works
Nykaza, I. R., Moy, A. P., Dusza, S. W., Moskowitz, A. J., Iyer, G., Iqbal, A. N., Motzer, R. J., Ilson, D. H., O'Cearbhaill, R. E., Kazi, R., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf208 · Cited by 19 · see citing works
Mehra, T., Dongre, K., Boesing, M., Frei, P., Suenderhauf, C., Zippelius, A., Leuppi, J. D., WICKI, A. N., & Leuppi-Taegtmeyer, A. B. (2023) · Cancer Medicine · doi:10.1002/cam4.5919 · Cited by 18 · see citing works
Jou, E. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00146 · Cited by 19 · see citing works
Temiz, M. Z., Çolakerol, A., Ulus, I., Kılıç, E., Paslanmaz, F., Şahin, S., Yürük, E., Kandıralı, E., Semerciöz, A., & Müslümanoğlu, A. Y. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02673-x · Cited by 19 · see citing works
Sibille, A., Henket, M. A., Corhay, J. L., Alfieri, R., Louis, R. E., & Duysinx, B. (2021) · Lung · doi:10.1007/s00408-021-00474-2 · Cited by 19 · see citing works
Aicher, A., Sindrilaru, A., Crișan, D., Thaiss, W. M., Steinacker, J., Beer, M., Wiegel, T., Scharffetter‐Kochanek, K., Beer, A. J., & Prasad, V. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071466 · Cited by 18 · see citing works
Insight into Cancer Immunity: MHCs, Immune Cells and Commensal Microbiota
Wen, M., Li, Y., Qin, X., Qin, B., & Wang, Q. A. (2023) · Cells · doi:10.3390/cells12141882 · Cited by 18 · see citing works
Donaubauer, A.-J., Rühle, P. F., Becker, I., Fietkau, R., Gaipl, U. S., & Frey, B. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_8 · Cited by 18 · see citing works
Innate Lymphoid Cells in Skin Homeostasis and Malignancy
Wagner, M., & Koyasu, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.758522 · Cited by 17 · see citing works
Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report
Occhipinti, M. A., Falcone, R., Onesti, C. E., & Marchetti, P. (2018) · Drug Safety - Case Reports · doi:10.1007/s40800-018-0078-z · Cited by 17 · see citing works
Sheng, L., Chen, X., Wang, Q., Lyu, S., & Li, P. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109966 · Cited by 17 · see citing works
Wendlinger, S., Wohlfarth, J., Kreft, S., Siedel, C., Kilian, T., Dischinger, U., Heppt, M. V., Wistuba‐Hamprecht, K., Meier, F. E., Goebeler, M., et al. (2022) · Cancers · doi:10.3390/cancers14092294 · Cited by 19 · see citing works
Eosinophils Decrease Pulmonary Metastatic Mammary Tumor Growth
Cederberg, R. A., Franks, S. E., Wadsworth, B. J., So, A., Decotret, L. R., Hall, M. G., Shi, R., Hughes, M. R., McNagny, K. M., & Bennewith, K. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.841921 · Cited by 16 · see citing works
Donaubauer, A.-J., Becker, I., Rühle, P. F., Fietkau, R., Gaipl, U. S., & Frey, B. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.03.003 · Cited by 15 · see citing works
Tailoring precision immunotherapy: coming to a clinic soon?
Han, S., Shuen, T. W. H., Wang, W.-W., Nazim, E., & Toh, H. C. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000631 · Cited by 15 · see citing works
Wagner, N. B., Luttermann, F., Gassenmaier, M., Forschner, A., Leiter, U., Garbe, C., & Eigentler, T. (2020) · Australasian Journal of Dermatology · doi:10.1111/ajd.13248 · Cited by 15 · see citing works
Takeuchi, E., Okano, Y., Machida, H., Atagi, K., Kondou, Y., Kadota, N., Hatakeyama, N., Naruse, K., & Shinohara, T. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02994-5 · Cited by 15 · see citing works
Yang, X., Wang, L., Du, H., Lin, B., Yi, J., Wen, X., Geng, L., & Du, X. (2021) · Medicine · doi:10.1097/md.0000000000024328 · Cited by 14 · see citing works
Rossari, F., Tada, T., Suda, G., Shimose, S., Kudo, M., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H. Y., Presa, J., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34799 · Cited by 14 · see citing works
Zhuang, T., Ravindranathan, D., Liu, Y., Martini, D. J., Brown, J. T., Nazha, B., Russler, G. A., Yantorni, L. B., Caulfield, S. E., Carthon, B. C., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac236 · Cited by 15 · see citing works
Omero, F., Speranza, D., Murdaca, G., Cavaleri, M., Marafioti, M., Cianci, V., Berretta, M., Casciaro, M., Gangemi, S., & Santarpía, M. (2025) · Biomolecules · doi:10.3390/biom15040491 · Cited by 13 · see citing works
Voutsadakis, I. A. (2020) · Chinese Clinical Oncology · doi:10.21037/cco.2020.03.03 · Cited by 13 · see citing works
Soto, F., Torre-Sada, L. F., Mott, F. E., Kim, S. T., Nurieva, R., Nagarajan, P., Guo, M., Shannon, V. R., Faiz, S. A., Casal, R. F., et al. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-30 · Cited by 11 · see citing works
Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma
Willems, M., Scherpereel, A., Wasielewski, E., Raskin, J., Brossel, H., Fontaine, A., Grégoire, M., Halkin, L., Jamakhani, M., Heinen, V., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148798 · Cited by 11 · see citing works
Gambale, E., Maruzzo, M., Messina, C. G. M., Aquino, I. D. G., Vascotto, I. A., Rossi, V., Bimbatti, D., Cavasin, N., Messina, M., Mennitto, A., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102099 · Cited by 12 · see citing works
Kartolo, A., Holstead, R. G., Hopman, W. M., & Baetz, T. D. (2020) · Immunotherapy · doi:10.2217/imt-2020-0265 · Cited by 11 · see citing works
Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors
Rogers, C. B. B., Zawislak, M. C., & Victoria Wong, P.-C. (2021) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2021.12.4.4 · Cited by 11 · see citing works
Ju, M., Fan, J., Zou, Y., Yu, M., Jiang, L., Wei, Q., Bi, J., Hu, B., Guan, Q., Song, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807840 · Cited by 10 · see citing works
Guardamagna, M., Berciano-Guerrero, M., Lavado-Valenzuela, R., Auclin, É., Onieva-Zafra, J.-L., Plaza-Andrades, I., Oliver, J., Garrido-Aranda, A., Pérez-Ruiz, E., Álvarez, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-11054-2 · Cited by 8 · see citing works
Grüninger, J., Lehr, S., Meiß, F., Rafei-Shamsabadi, D. A., & Schauer, F. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1613552 · Cited by 9 · see citing works
Chen, S., Zhang, L., Lin, H., Liang, Y., & Wang, Y. (2022) · Biomolecules · doi:10.3390/biom13010058 · Cited by 9 · see citing works
Eosinophils in metastatic melanoma
Proffer, S. L., Guo, R., Demer, A. M., & Peters, M. S. (2023) · Human Pathology · doi:10.1016/j.humpath.2023.08.001 · Cited by 9 · see citing works
Moreira, A., Erdmann, M., Uslu, U., Vass, V., Schuler, G., & Schuler‐Thurner, B. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030210 · Cited by 9 · see citing works
Wu, Y., Yang, J., Qiao, X., Li, Y., Zhao, R., Lin, T., Li, X., & Wang, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1041140 · Cited by 8 · see citing works
Singh, N., Lubana, S. S., Constantinou, G., & Leaf, A. N. (2020) · Case Reports in Oncological Medicine · doi:10.1155/2020/7492634 · Cited by 8 · see citing works
Şahin, G., Acar, C., Yüksel, H. Ç., Tünbekici, S., Açar, F. P., Çelebi, G., & Karaca, B. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04024-7 · Cited by 7 · see citing works
Chen, S., Zhang, L., Huang, M., Liang, Y., & Wang, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190660 · Cited by 7 · see citing works
Manger, I., Schmitt, C., Berking, C., French, L. E., Vera, J., & Heinzerling, L. M. (2025) · BMC Cancer · doi:10.1186/s12885-025-13857-y · Cited by 6 · see citing works
A rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma
Tsuji, A., Hiramatsu, K., Namikawa, S., Yamamoto, A., Midori, Y., Murata, Y., Tanaka, T., Nosaka, T., Naito, T., Takahashi, K., et al. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-022-01680-y · Cited by 6 · see citing works
Apprising Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma—Persistent Updating
Georgescu, S. R., Mitran, C. I., Mitran, M. I., Matei, C., Constantin, C., Neagu, M. T., & Tampa, M. Ş. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091506 · Cited by 6 · see citing works
Brand, C. L., Hunger, R. E., & Jafari, S. M. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1366081 · Cited by 6 · see citing works
Wang, J., Li, F., Xu, Y., Zheng, X., Zhang, C., Hu, C., Xu, Y., Mi, W., Li, X., & Zhang, Y. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02962-8 · Cited by 6 · see citing works
Eosinophil ETosis and Cancer: Ultrastructural Evidence and Oncological Implications
Caruso, R. A., Caruso, V., & Rigoli, L. C. (2025) · Cancers · doi:10.3390/cancers17193250 · Cited by 5 · see citing works
Vacher, L., Bernadach, M., Molnar, I., Passildas, J., & Dubray‐Longeras, P. (2024) · Health Science Reports · doi:10.1002/hsr2.1825 · Cited by 4 · see citing works
- Authors
- Moreira, A., Leisgang, W., Schuler, G., & Heinzerling, L.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Venue
- Immunotherapy
- Publisher
- Informa UK Limited
- Published
- 2017-01-27
- Volume
- 9
- Issue
- 2
- Pages
- 115-121
- ISSN
- 1750-743X (ISSN-L)
- 1750-7448
- OpenAlex
- W2581911737
- Cited by
- 147
- References
- 32
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 9 · 2023: 18 · 2022: 28 · 2021: 22 · 2020: 24 · 2019: 9 · 2018: 7 · 2017: 6
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Immunotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- eosinophilia, eosinophil count, metastatic melanoma, prognostic factors, survival, immune checkpoint inhibitors, pembrolizumab, ipilimumab, blood eosinophils
- MeSH terms
- Adult, Aged, Aged, 80 and over, Animals, Cell Count, Eosinophils, Female, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor, Survival Analysis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
